Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Narita, Shintaro ^a   Tsuchiya, Norihiko ^a   Kumazawa, Teruaki ^b   Maita, Shinya ^a   Numakura, Kazuyuki ^a   Obara, Takashi ^a   Tsuruta, Hiroshi ^a   Saito, Mitsuru ^a   Inoue, Takamitsu ^a   Horikawa, Yohei ^a   Satoh, Shigeru ^a   Nanjyo, Hiroshi ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Senboku General Hospital   (Japan)

Author keywords

Androgen deprivation; Chemohormonal therapy; Complete androgen blockade; Docetaxel; Estramustine phosphate; Prostate cancer

Indexed keywords

BICALUTAMIDE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANDROGEN; ANILIDE; ANTINEOPLASTIC AGENT; ESTRAMUSTINE; NITRILE; TAXOID; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; JAPANESE; LEUKOPENIA; LYMPHOCELE; MULTIPLE CYCLE TREATMENT; NAUSEA; PELVIS LYMPHADENECTOMY; POSTOPERATIVE COMPLICATION; PROSTATE CANCER; PROSTATECTOMY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URETER INJURY; VOMITING; ADJUVANT THERAPY; CANCER STAGING; FEMALE; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANDROGENS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ESTRAMUSTINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84855280884     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-1     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer?. Urology 76:710-714.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998, 280:969-974. 10.1001/jama.280.11.969, 9749478.
4. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998, 160:2428-2434. 10.1016/S0022-5347(01)62204-3, 9817397.
5. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009, 35:9-17. 10.1016/j.ctrv.2008.08.002, 18926640.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. 10.1056/NEJMoa040720, 15470213.
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520. 10.1056/NEJMoa041318, 15470214.
8. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004, 63:1138-1142. 10.1016/j.urology.2004.01.040, 15183967.
9. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005, 11:5233-5240. 10.1158/1078-0432.CCR-05-0299, 16033841.
10. Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 2007, 100:274-280. 10.1111/j.1464-410X.2007.06760.x, 17355369.
11. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008, 180:565-570. discussion 570, 10.1016/j.juro.2008.04.012, 18554663.
12. Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 2008, 71:323-327. 10.1016/j.urology.2007.08.060, 18308112.
13. Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer 2009, 101:1248-1252. 10.1038/sj.bjc.6605320, 2768456, 19755998.
14. Miyake H, Fujimoto H, Komiyama M, Fujisawa M. Development of "extended radical retropubic prostatectomy": a surgical technique for improving margin positive rates in prostate cancer. Eur J Surg Oncol 36:281-286.
15. Freiha FS, Salzman J. Surgical staging of prostatic cancer: transperitoneal versus extraperitoneal lymphadenectomy. J Urol 1977, 118:616-617.
16. pathology JUAtJso General rule for clinical and pathological studies on prostate cancer 2010, Tokyo: Kanehara, 4, pathology JUAtJso.
17. Sitka Copur M, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, Norvell M, Muhvic J, Hake L, Wendt J. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001, 28:16-21.
18. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005, 11:4905-4911. 10.1158/1078-0432.CCR-04-2140, 16000589.
19. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562-4567.